|
|
Volumn 11, Issue 6, 2012, Pages 425-426
|
|
The gout pipeline crystallizes
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALLOPURINOL;
ANTIINFLAMMATORY AGENT;
ARHALOFENATE;
BCX 4208;
CANAKINUMAB;
COLCHICINE;
FEBUXOSTAT;
LESINURAD;
NONSTEROID ANTIINFLAMMATORY AGENT;
RILONACEPT;
TOFISOPAM;
UNCLASSIFIED DRUG;
URIC ACID;
URICOSURIC AGENT;
XANTHINE OXIDASE INHIBITOR;
COST EFFECTIVENESS ANALYSIS;
DISEASE ASSOCIATION;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG SAFETY;
GOUT;
HUMAN;
HYPERURICEMIA;
PRIORITY JOURNAL;
RISK FACTOR;
RISK REDUCTION;
SHORT SURVEY;
TREATMENT INDICATION;
URIC ACID BLOOD LEVEL;
ALLOPURINOL;
ANTI-INFLAMMATORY AGENTS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG INDUSTRY;
GOUT;
GOUT SUPPRESSANTS;
HUMANS;
URIC ACID;
|
|
EID: 84861919736
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3748 Document Type: Short Survey |
|
Times cited : (8)
|
|
References (0)
|
